Carl Zeiss Meditec


Carl Zeiss Meditec’s re-rating journey should continue further

21/02/24 -"Despite our near-term estimates being slightly moderated due to the destocking of consumables and anticipated impact from volume-based procurement headwinds, our target price resets higher by c.4%, ..."

Pages
65
Language
English
Published on
21/02/24
You may also be interested by these reports :
11/12/24
CZM’s FY2023-24 operational performance came in line with the management’s expectations, as a weaker investment climate in North America and soft ...

05/12/24
Since we last teased the in-vitro diagnostics player DiaSorin (Add; Italy) in August 2023, the Italian firm has seen its dreams become reality. The ...

02/12/24
Even though Philips and Siemens Healthineers share a decent overlap in business areas and Philips has a better report card in terms of stakeholder ...

27/11/24
Elekta’s Q2 results missed the street’s expectations. Topline growth declined by a mid-single digit percentage as healthy growth in Service was more ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO